Israel's Teva and Procognia to Collaborate on Biopharmaceuticals | GenomeWeb
NEW YORK (GenomeWeb News) – Teva Pharmaceutical Industries and the Israeli subsidiary of protein array company Procognia will collaborate on two biopharmaceutical products, the companies said today.
 
Under the agreement, Teva will have exclusive access to Procognia Israel’s glycoanalysis technology and related services.
 
Procognia will receive milestone and royalty payments from Teva, which will finance the collaboration.
 
Additional financial details were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.